TScan Therapeutics, Inc.
TCRX Healthcare Biotechnology
TScan Therapeutics, Inc.’s revenue for fiscal 2025 (year ended December 2025) was $10.3 million, up 266.7% from fiscal 2024. In the quarter to June 2026, revenue fell 65.8%, EPS grew 17.9%, free cash flow grew 19.0% and total debt rose 1.50%, each against the same quarter a year earlier. Insiders bought in the last twelve months.
Follow TCRX
TScan Therapeutics, Inc. (TCRX) P/E ratio
TScan Therapeutics, Inc. has no meaningful P/E ratio: its trailing twelve-month earnings is negative. Over the past ten years it has ranged from 0.0× (October 2026) to 2.2× (May 2022) — the current reading is the lowest in ten years.
P/E ratio, daily
Embed this chart
Annual newest first
| Period | P/E ratio | Change |
|---|---|---|
| FY2025 | 0.0× | — |
| FY2024 | 0.0× | — |
| FY2023 | 0.0× | — |
| FY2022 | 0.0× | — |
| FY2021 | 0.0× | — |
| FY2020 | 0.0× | — |
Quarterly newest first
| Period | P/E ratio | Change |
|---|---|---|
| Jun 2026 | 0.0× | — |
| Mar 2026 | 0.0× | — |
| Dec 2025 | 0.0× | — |
| Sep 2025 | 0.0× | — |
| 20 more quarters | Free account |
Against its own ten years
P/E ratio against peers
| Company | P/E ratio |
|---|---|
| DYAI Dyadic International Inc. compare | n/m |
| MRKR MARKER THERAPEUTICS, INC. compare | n/m |
| TCRX TScan Therapeutics, Inc. | n/m |
| ACGN Aceragen, Inc. compare | n/m |
| AKTX Akari Therapeutics PLC compare | n/m |
| NCEL NewcelX Ltd. compare | n/m |
| VAXX Vaxxinity, Inc. compare | n/m |
| PBM Psyence Biomedical Ltd. compare | 0.2× |
| RADX Radiopharm Theranostics Limited - Sponsored ADR compare | — |
| Biotechnology industry median | 8.5× |
| Healthcare sector median | 23.0× |
| Market median | 18.1× |
What P/E ratio is
Price to Earnings Ratio shows how much investors pay for each dollar of a company’s annual profit per share.
Stock Price ÷ EPS (Basic) (TTM)